Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels

Clinical Infectious Diseases

Volumn 58, Issue 8, 2014, Pages 1156-1164

  Santoro, Maria Mercedes ^a   Fabeni, Lavinia ^b   Armenia, Daniele ^a   Alteri, Claudia ^a   Di Pinto, Domenico ^a   Forbici, Federica ^b   Bertoli, Ada ^a,c   Di Carlo, Domenico ^a   Gori, Caterina ^b   Carta, Stefania ^b   Fedele, Valentina ^b   D'Arrigo, Roberta ^b   Berno, Giulia ^b   Ammassari, Adriana ^b   Pinnetti, Carmela ^b   Nicastri, Emanuele ^b   Latini, Alessandra ^d   Tommasi, Chiara ^b   Boumis, Evangelo ^b   Petrosillo, Nicola ^b   D'Offizi, Gianpiero ^b   Andreoni, Massimo ^a,c   Ceccherini Silberstein, Francesca ^a   Antinori, Andrea ^b   Perno, Carlo Federico ^a,b,c   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b L Spallanzani Hospital   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

clinical outcome; drug resistance; HIV 1 genotyping; HIV 1 low viremia; phylogenesis

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; DIAGNOSTIC VALUE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; GENOTYPIC RESISTANCE TESTING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; VIREMIA; VIRUS DETECTION; VIRUS MUTATION; ADULT; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HIV INFECTIONS; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ADULT; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84897431077     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu020     Document Type: Article

References (40)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. European AIDS Clinical Society Guidelines (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 7.0, October 2013. Available at: http://www.eacsociety.org/Portals/0/Guidelines- Online-131014.pdf. Accessed 22 July 2013.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
4. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 2013. Available at: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 July 2013.
5. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000; 284:223-8.
6. Gutierrez F, Padilla S, Masiá M, et al. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS One 2006; 1:e89.
7. Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIVinfected persons in care: reducing disparities. Clin Infect Dis 2012; 55:1242-51.
8. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-305.
9. Cozzi-Lepri A, Mussini C, Bonora S, et al. The chance of suppressing viral load ?80 copies/ml according to initial viral load and type of regimen started: an observational study. In: 13th European AIDS Conference/European AIDS Clinical Society Guidelines (EACS). Belgrade, Serbia, 12-15 October 2011. Abstract PE7.7/3.
10. Santoro MM, Armenia D, Alteri C, et al. Impact of pre-therapy viral load on virological response to modern first-line HAART. Antiv Ther 2013. doi:10.3851/IMP2531.
11. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72:2422-8.
12. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatmentexperienced patients. AIDS 2000; 14:2877-87.
13. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-44.
14. Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 2012; 7:e36673. doi:10.1371/journal.pone.0036673.
15. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, et al. European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13:77-108.
16. Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods 2004; 119:73-81.
17. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV- 1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1030-7.
18. Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol 2006; 13:235-8.
19. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mL. AIDS 2006; 20:778-9.
20. Mitsuya Y, Winters MA, Fessel WJ, et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr 2006; 43:56-9.
21. Cane PA, Kaye S, Smit E, et al. Genotypic antiretroviral drug resistance at low viral loads in the UK. HIV Med 2008; 9:673-6.
22. Yang Z, Morrison R, Oates C, et al. HIV-1 genotypic resistance testing on low viral load specimens using the Abbott ViroSeq HIV-1 genotyping system. Lab Med 2008; 39:671-3.
23. Pattery T, De Wolf H, Verlinden Y, et al. Efficiency of HIV-1 PR-RT genotyping on clinical isolates with viral load less than 1000 copies/mL: a 12 year analysis. In: 8th European HIV Drug Resistance Workshop, Sorrento, Italy, 2010. Poster 1.
24. Milia MG, Allice T, Gregori G, et al. Magnetic-silica based nucleic acid extraction for human immunodeficiency virus type-1 drug-resistance testing in low viremic patients. J Clin Virol 2010; 47:8-12.
25. Stelzl E, Troppan KT, Winkler M, et al. Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load. J Virol Methods 2010; 168:152-4.
26. Gonzalez-Serna A, Min JE, Woods C, Li J, Harrigan PR, Swenson LC. Low level HIV viremia and drug resistance testing. In: 20th Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 2013. Poster 601.
27. Ruelle J, Jnaoui K, Lefèvre I, et al. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009; 44:297-301.
28. Paba P, Fabeni L, Ciccozzi M, et al. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J Virol Methods 2011; 173:399-402.
29. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr 2011; 56:239-43.
30. Ceccherini-Silberstein F, Gago F, Santoro M, et al. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol 2005; 79:10718-29.
31. Mukaide M, Sugiura W, Matuda M, et al. Evaluation of ViroSeq-HIV version 2 for HIV drug resistance. Jpn J Infect Dis 2000; 53:203-5.
32. Cunningham S, Ank B, Lewis D, et al. Performance of the Applied Biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol 2001; 39:1254-7.
33. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16:111-20.
34. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21:6-14.
35. Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010; 201:1303-7.
36. Prosperi MC, Mackie N, Di Giambenedetto S, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011; 66: 1886-96.
37. Swenson LC, Gonzalez-Serna A, Min J, Woods CK, Li JZ, Harrigan PR. HIV drug resistance occurring during low-level viraemia is associated with subsequent virological failure. Abstract
38. Program and abstracts of the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies (Toronto, Canada). Antiviral Ther 2013; 18(suppl 1):A40.
39. Assoumou L, Descamps D, Yerly S, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother 2013; 68: 1400-05.
40. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9:811-8.